Reported Earlier, BridgeBio Reports New Data Suggesting Attruby Could Help Reverse Some Heart Damage
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, presented new
BridgeBio shared test results showing their heart medicine might help fix some damage to hearts. When a company announces good research results, it's worth watching to see if doctors and patients will actually want to use the medicine.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.